Send to

Choose Destination
Wien Med Wochenschr. 2015 Oct;165(19-20):410-8. doi: 10.1007/s10354-015-0379-0. Epub 2015 Aug 25.

EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice.

Author information

hemetsberger medical services, Vienna, Austria.
3rd Internal Department -Kidney diseases and high pressure conditions, transplant medicine, rheumatology, Elisabethinen Hospital, Linz, Austria.
Clinical Trials Management GmbH, Vienna, Austria.
Department of Internal Medicine, Dialysis Unit, Krankenhaus der Barmherzigen Brüder, Johannes von Gott Platz 1, 7001, Eisenstadt, Austria.


The EARLIER (Evaluation of MimpARa in incident hemodiaLysis patIEnts with secondaRy hyperparathyroidism; SHPT) observational postmarketing surveillance study evaluated incident hemodialysis patients (< 1 year dialysis vintage; n = 146) receiving cinacalcet in Austrian clinical practice. Despite intervention with vitamin D sterols and phosphate binders, 24 % had already developed severe SHPT (intact parathyroid hormone (iPTH) > 800 pg/mL) at baseline. After cinacalcet was started, median iPTH decreased substantially, from 611 pg/mL to 251 pg/mL (median decrease 58 % [IQR - 36 to - 78 %] at 12 months. Overall, 36 % of patients achieved the Kidney Disease Outcomes Quality Initiative (K/DOQI) target range (150-300 pg/mL) for iPTH; this included 35 % of those with severe SHPT at baseline. Serum phosphorus (P), calcium (Ca) (corr), and Ca (corr) × P also decreased, with 43, 34, and 62 % of patients, respectively, reaching K/DOQI targets at 12 months. Thus, in this observational study, mineral metabolism in incident dialysis patients with SHPT improved after starting cinacalcet.


Calcimimetic; Cinacalcet; Dialysis; Incident dialysis; Secondary hyperparathyroidism

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center